The Extremely Atypical Everolimus Story
18, p?Cofactor [t(46)?=?1.09, p?=?0.28; Cohen's d?=?0.47] in terms of the P1 response to red�Cgreen stimuli. Figure 2 Relative amplitude (��V) of the VEP response to chromatic onset stimuli (left?=?blue�Cyellow, right?=?red�Cgreen). Additional analysis was conducted using achromatic stimuli (luminance), although these stimuli were used primarily as an experimental control condition designed to prevent saturation Everolimus clinical trial of the color vision system. No significant intergroup differences were found in amplitude or latency for achromatic stimuli (see Table 2). Inattentive symptoms from parent ratings on the SWAN correlated significantly with P1 amplitude in response to B�CY stimuli [r(27)?=??0.386, p?=?0.046] but not for R�CG stimuli [r(27)?=??0.195, selleckchem p?=?0.330], indicating that more severe inattention was related to greater P1 amplitude for B�CY (see scatter plot in Fig. 3). By contrast, there was no significant relationship between hyperactivity/impulsivity scores and the P1 amplitude for either B�CY [r(27)?=??0.286, p?=?0.146 or R�CG stimuli [r(27)?=??0.132, p?=?0.495]. Figure 3 Scatter plot between Inattentive symptom on SWAN and relative P1 amplitude (��V) on blue�Cyellow. Discussion This study represents the first attempt to use cVEP to assay color perception in an ADHD sample. Moreover, we conducted ophthalmological testing to allow us to disaggregate color perception problems from problems in vision. The major findings in this pilot study were that: (1) the ADHD group (particularly the ��medicated�� group) showed a much larger P1 amplitude in response to blue�Cyellow stimuli than did the comparison group, but did not differ in terms of the P1 latency; (2) there were no intergroup differences in the P1 amplitude or latency in response to red�Cgreen or achromatic stimuli; (3) inattention significantly correlated with the P1 amplitude, only for B�CY stimuli; and (4) there was no evidence in ophthalmological problems in the ADHD group based on the clinical measures.
